Industry News Roundup
This article was originally published in The Tan Sheet
Executive Summary
DASCA facilitates DEA’s steroid scheduling; U.K. ad authority sneezes at hay fever claim; Nutroganics acquires Wholesoy; hemp migraine relief distribution lit; Clif’s cashew recipe trips some customers; ONHA sponsors GrassrootsHealth nutrient research; baby wipe recall reaches 4M units; and Nasdaq reprieve for Rock Creek.
You may also be interested in...
States’ Proposals To Age-Restrict Sports Nutrition Sales Miss Targeted Problems But Hit Retailers
MA and NY lawmakers propose prohibiting sales to consumers under 18 of supplements, OTC drugs for weight loss and muscle building and imposing $2,000 fines for violations. Supplement industry trade groups say the laws would not help solve eating disorders but would hammer retailers.
US DoJ Has 'Key Focus' On Supplement Industry, Adds 6 Attorneys To Sector
"It is just common sense that there's going to be fraud where you have the combination of high growth, developing science, imported products or ingredients and limited oversight," says David Morrell, deputy assistant US attorney in DoJ'd Consumer Protection Branch. CPB
SARMs Subject To Steroids Scheduling By DEA Under Hatch, Whitehouse Bill
The Utah Republican and Rhode Island Democrat sponsor legislation to make selective androgen receptor modulators subject to the same authority the Drug Enforcement Administration has to regulate anabolic steroids. Hatch said the SARMs Control Act of 2018 would "ensure that the DEA has the authority it needs to prevent abuse and diversion of these dangerous substances.”